Loading...
Publication
Braquiterapia endobrônquica de alta taxa de dose como tratamento paliativo : artigo de revisão
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 7.03 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Objetivo
Este trabalho tem como objetivos primordiais
o estudo de critérios de elegibilidade para a
Braquiterapia Endobrônquica, a análise dos
benefícios clínicos como terapêutica paliativo e a
procura de esquemas de fracionamentos de dose
mais vantajosos.
Materiais e Métodos
A amostra compreendeu artigos do ano de 2000
até 2019. A revisão sistemática tem como amostra
24 artigos. Critérios de inclusão: Estudos onde
se comprovou a relevância da braquiterapia no
tratamento paliativo na patologia pulmonar, com
discriminação de como foi realizado esse estudo;
Estudos em doentes em cuidados paliativos;
Estudos que salientam os requisitos à realização da
braquiterapia paliativa. Critério de exclusão: estudos
de braquiterapia endobrônquica de abordagem
curativa.
Resultados Principais
O tempo médio de follow-up mais usual foi de 6
meses, já o tempo médio de sobrevida variou entre
os 3-54 meses. Os brônquios são as estruturas mais
atingidas. Como critérios de elegibilidade, a prova
histológica e broncoscópica, a sintomatologia
persistente e a impossibilidade de operar o tumor,
foram os mais observados. A hemoptise fatal, a
hemoptise e a bronquite por radiação foram as
complicações mais registadas.
Conclusão
São necessários critérios de elegibilidade para
realizar o tratamento. A braquiterapia acarreta
uma maior toxicidade comparativamente à RTE, no
entanto ajuda no alívio de sintomas. As guidelines
sugerem 3# de 7.5Gy, 2# de 10Gy ou 4# de 6Gy
quando a braquiterapia é utilizada sozinha.
ABSRACT: Objective Demonstrating if it is possible to demonstrate eligibility criteria, how high dose rate brachytherapy could help in palliative treatment and an adequate dose frac-tionation scheme. Materials and Methods Demonstrating if it is possible to demonstrate eligibility criteria, how high dose rate brachytherapy could help in palliative treatment and an adequate dose frac-tionation scheme. Materials and Methods The analysis comprised articles from the year 2000 to 2019. The systematic review has 24 articles as a sample. Inclusion criteria: Studies that show the importance of brachytherapy in palliative treatment in pulmonary pathology, with a description of how this study was done; Studies in patients in palliative care; Studies that show the requirements for palliative brachytherapy. Exclusion criteria: studies with a curative approach. Main results The most common mean follow-up time was 6 months since the mean survival time ranged from 3-54 months. The bronchi was the structure more affected. As a criteria, the histologic and bronchoscopy prove, the persistent symptomatology and a good performance status, were the most observed. Fatal hemoptysis, hemoptysis, and radiation bronchitis were the most frequently recorded. Conclusion Eligibility criteria are necessary to carry out the treatment. Brachytherapy entails greater toxicity compared to EBR. The risk of fatal hemoptysis is quite high. The guidelines suggests 3 # of 7.5Gy, 2 # of 10Gy or 4 # of 6Gy when a Brachythera-py is alone.
ABSRACT: Objective Demonstrating if it is possible to demonstrate eligibility criteria, how high dose rate brachytherapy could help in palliative treatment and an adequate dose frac-tionation scheme. Materials and Methods Demonstrating if it is possible to demonstrate eligibility criteria, how high dose rate brachytherapy could help in palliative treatment and an adequate dose frac-tionation scheme. Materials and Methods The analysis comprised articles from the year 2000 to 2019. The systematic review has 24 articles as a sample. Inclusion criteria: Studies that show the importance of brachytherapy in palliative treatment in pulmonary pathology, with a description of how this study was done; Studies in patients in palliative care; Studies that show the requirements for palliative brachytherapy. Exclusion criteria: studies with a curative approach. Main results The most common mean follow-up time was 6 months since the mean survival time ranged from 3-54 months. The bronchi was the structure more affected. As a criteria, the histologic and bronchoscopy prove, the persistent symptomatology and a good performance status, were the most observed. Fatal hemoptysis, hemoptysis, and radiation bronchitis were the most frequently recorded. Conclusion Eligibility criteria are necessary to carry out the treatment. Brachytherapy entails greater toxicity compared to EBR. The risk of fatal hemoptysis is quite high. The guidelines suggests 3 # of 7.5Gy, 2 # of 10Gy or 4 # of 6Gy when a Brachythera-py is alone.
Description
Keywords
Brachytherapy Lung neoplasm Neo-plasm metastasis Palliative treatment
Citation
PERDIGÃO, Maria ; HENRIQUES, Dina (2020) - Braquiterapia endobrônquica de alta taxa de dose como tratamento paliativo : artigo de revisão. HIGEIA : Revista Científica da Escola Superior de Saúde Dr. Lopes Dias. ISSN 2184-5565. Ano II, vol. 3, n.º 1, p. 9-23.
Publisher
IPCB. ESALD